Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy
(RTTNews) - Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for upto $47 million, helping advance the latter's pipeline, which includes AVC-201 for the treatment of relapsed/refr
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.